Ovements in renal osteodystrophy in patients treated with lanthanum carbonate for two years. Clin Nephrol 2008, 70:284?95. 22. Spasovski GB, Sikole A, Gelev S, Masin-Spasovska J, Freemont T, Webster I, Gill M, Jones C, De Broe ME, D’Haese Pc: Evolution of bone and plasma concentration of lanthanum in dialysis sufferers just before, in the course of 1 year of remedy with lanthanum carbonate and after 2 years of follow-up. Nephrol Dial Transplant 2006, 21:2217?224. 23. Finn WF, SPD 405?07 Lanthanum Study Group: Lanthanum carbonate versus common therapy for the therapy of hyperphosphatemia: security and efficacy in chronic upkeep hemodialysis patients. Clin Nephrol 2006, 65:191?02. 24. Wilson R, Zhang P, Smyth M, Pratt R: Assessment of survival in a 2-year comparative study of lanthanum carbonate versus regular therapy. Existing Healthcare Investigation Opinion 2009, 25:3021?028. 25. Navaneethan SD, Palmer SC, Craig JC, Elder GJ, Strippoli GF: Advantages and harms of phosphate binders in CKD: a systematic overview of randomized controlled trials. Am J Kidney Dis 2009, 54:619?37. 26. Higgins JPT, Green S: Cochrane Handbook for Systematic Testimonials of Interventions Version 5.0.0 [updated February 2008]. The Cochrane Collaboration 2008: Editors Accessible from cochrane-handbook.org. 27. Altmann P, Barnett ME, Finn WF: Cognitive function in Stage 5 chronic kidney illness individuals on hemodialysis: no adverse effects of lanthanum carbonate compared with typical phosphate-binder therapy. Kidney Int 2007, 71:252?59. 28. Mehrotra R, Martin KJ, Fishbane S, Sprague SM, Zeig S, Anger M, Fosrenol Overview Study Evaluation Study for Early Expertise Study Group: Greater strength lanthanum carbonate offers serum phosphorus manage using a low tablet burden and is preferred by patients and physicians: a multicenter study. J Am Soc Nephrol 2008, three:1437?445. 29. Toida T, Fukudome K, Fujimoto S, Yamada K, Sato Y, Chiyotanda S, Kitamura K: Impact of lanthanum carbonate vs.Formula of 9-Oxo-9H-fluorene-4-carboxylic acid calcium carbonate on serum calcium in hemodialysis individuals: a crossover study.3-Fluoro-2-methyl-6-nitropyridine supplier Clin Nephrol 2012, 78:216?23.PMID:33574032 30. Alastair Hutchison J, Bart M, Johan V, Gernot A, Elfatih M, Roland S, Wolfgang B, Rene J, Andre V: Long-Term Efficacy and Tolerability of Lanthanum Carbonate: Results from a 3-Year Study. Nephron Clin Pract 2006, 102:61?1.Zhang et al. BMC Nephrology 2013, 14:226 http://biomedcentral/1471-2369/14/Page 14 of31. Hutchison AJ, Maes B, Vanwalleghem J, Asmus G, Mohamed E, Schmieder R, Backs W, Jamar R, Vosskuhler A: Efficacy, tolerability, and security of lanthanum carbonate in hyperphosphatemia: a 6-month, randomized, comparative trial versus calcium carbonate. Nephron Clin Pract 2005, one hundred:8?9. 32. Sprague SM, Ross EA, Nath SD, Zhang P, Pratt RD, Krause R: Lanthanum carbonate vs. sevelamer hydrochloride for the reduction of serum phosphorus in hemodialysis patients: a crossover study. Clin Nephrol 2009, 72:252?58. 33. Kasai S, Sato K, Murata Y, Kinoshita Y: Randomized crossover study of your efficacy and safety of sevelamer hydrochloride and lanthanum carbonate in Japanese individuals undergoing hemodialysis. Ther Apher Dial 2012, 16:341?49. 34. Shigematsu T, along with the Lanthanum Carbonate Research Group: Lanthanum carbonate successfully controls serum phosphate with out affecting serum calcium levels in patients undergoing hemodialysis. Ther Apher Dial 2007, 12:55?1. 35. Shigematsu T, And the Lanthanum Carbonate Group: Multicenter prospective randomized, double-blind comparative study among lanthanum carbo.